{
    "ticker": "SANA",
    "name": "Sana Biotechnology, Inc.",
    "description": "Sana Biotechnology, Inc. is a leading biotechnology company focused on creating and delivering engineered cells as medicines for patients. Founded in 2018 and based in Seattle, Washington, Sana's mission is to unlock the potential of cell therapy to treat various diseases and conditions, including genetic disorders, cancer, and degenerative diseases. The company utilizes advanced technologies in gene editing and cell engineering to develop innovative therapies that can modify cells to restore or replace the function of damaged or diseased tissues. Sana's pipeline includes a range of product candidates that aim to address significant unmet medical needs, with a particular emphasis on precision medicine approaches. The company is committed to scientific excellence and collaboration, partnering with top-tier research institutions and leveraging cutting-edge research to advance its therapeutic programs. Sana Biotechnology is dedicated to ensuring that its therapies are accessible and that they improve the quality of life for patients worldwide.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Seattle, Washington, USA",
    "founded": "2018",
    "website": "https://www.sanabiotechnology.com",
    "ceo": "Steve Harr",
    "social_media": {
        "twitter": "https://twitter.com/sanabiotech",
        "linkedin": "https://www.linkedin.com/company/sanabiotechnology/"
    },
    "investor_relations": "https://investors.sanabiotechnology.com",
    "key_executives": [
        {
            "name": "Steve Harr",
            "position": "CEO"
        },
        {
            "name": "Brett Monia",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Cell Therapies",
            "products": [
                "Gene-Edited Cell Therapies",
                "Engineered Cell Replacement Therapies"
            ]
        }
    ],
    "seo": {
        "meta_title": "Sana Biotechnology, Inc. | Engineered Cells as Medicines",
        "meta_description": "Explore Sana Biotechnology, Inc., a leader in engineered cell therapies aimed at treating genetic disorders and diseases. Learn about their innovative approaches and product pipeline.",
        "keywords": [
            "Sana Biotechnology",
            "Cell Therapy",
            "Gene Editing",
            "Biotechnology",
            "Pharmaceuticals",
            "Cancer Treatment",
            "Genetic Disorders"
        ]
    },
    "faq": [
        {
            "question": "What is Sana Biotechnology focused on?",
            "answer": "Sana Biotechnology focuses on creating engineered cells as medicines to treat various diseases, including genetic disorders and cancer."
        },
        {
            "question": "Who is the CEO of Sana Biotechnology?",
            "answer": "Steve Harr is the CEO of Sana Biotechnology, Inc."
        },
        {
            "question": "Where is Sana Biotechnology headquartered?",
            "answer": "Sana Biotechnology is headquartered in Seattle, Washington, USA."
        },
        {
            "question": "What types of therapies does Sana develop?",
            "answer": "Sana develops gene-edited cell therapies and engineered cell replacement therapies."
        },
        {
            "question": "When was Sana Biotechnology founded?",
            "answer": "Sana Biotechnology was founded in 2018."
        }
    ],
    "competitors": [
        "EDIT",
        "CRSP",
        "SGMO",
        "AMGN"
    ],
    "related_stocks": [
        "NVDA",
        "AAPL",
        "AMZN",
        "MSFT"
    ]
}